Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder
Lund, Sweden — 13 January 2022 — Camurus (NASDAQ STO: CAMX) today announces that the company’s license partner Rhythm Pharmaceuticals has dosed the first patients in a Phase 3 trial evaluating weekly setmelanotide subcutaneous depot in patients six years of age and older with a rare genetic disease of obesity. “We are pleased with the progress of our collaboration with Rhythm and today’s announcement of the first dosing in a randomized controlled Phase 3 trial of our long-acting formulation of setmelanotide in patients with rare genetic obesity disorders.” says Dr. Fredrik Tiberg, CEO